Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Research & Development (2020 - 2025)

Historic Research & Development for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $5.4 million.

  • Barinthus Biotherapeutics' Research & Development fell 5161.15% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year decrease of 2569.79%. This contributed to the annual value of $42.2 million for FY2024, which is 587.87% down from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Research & Development stood at $5.4 million, which was down 5161.15% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Research & Development registered a high of $15.1 million during Q3 2023, and its lowest value of $4.4 million during Q3 2021.
  • Over the past 5 years, Barinthus Biotherapeutics' median Research & Development value was $9.7 million (recorded in 2022), while the average stood at $9.0 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 16816.06% in 2021, then crashed by 5161.15% in 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Research & Development (Quarter) stood at $6.9 million in 2021, then surged by 77.08% to $12.2 million in 2022, then crashed by 47.7% to $6.4 million in 2023, then soared by 30.39% to $8.3 million in 2024, then tumbled by 35.14% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $8.0 million for Q2 2025, and $8.3 million during Q1 2025.